clinical decision-making and pharmaceutical R&D. [Clinical Leadership & Market Presence] Originally established as the first official spin-off from Samsung Medical Center (SMC), AIVIS has rapidly transitioned from research to routine clinical practice. -Market Adoption: Within one year of regulatory approval, AIVIS's solutions have been deployed in over 20 leading hospitals in South Korea, capturing approximately 25% of the domestic market. -Proven Utility: In large-scale clinical studies involving 38 pathologists across 20 institutions, AIVIS demonstrated a significant reduction in inter-observer variability, drastically improving diagnostic consistency in complex cases. [Strategic Partnerships with Global Leaders] AIVIS is at the forefront of building a global digital pathology ecosystem through high-level strategic collaborations: -AstraZeneca: Signed an MOU to develop an AI-powered HER2 diagnostic ecosystem, optimizing patient screening for next-generation therapies like Antibody-Drug Conjugates (ADCs). -Philips Korea: Secured a License Agreement to integrate AIVIS’s quantification engines (Qanti® IHC) into Philips’ global pathology solutions, enhancing diagnostic workflows for various cancer biomarkers. [Comprehensive Product Portfolio] -Qanti® IHC: An MFDS-approved clinical decision support software designed for high-accuracy patient screening in routine clinical environments. It ensures auditable and regulatory-compliant data for formal diagnosis. -Qanti® Discovery: A translational research tool that automates cell quantification for drug development. It streamlines reporting for regulatory submissions and accelerates decision-making in clinical trials by providing standardized scoring. [Vision for Precision Medicine] AIVIS is continuously expanding its capabilities beyond breast and gastric cancers to include lung, prostate, and colon cancers. By co-developing specialized tools with global pharmaceutical partners, AIVIS is bridging the gap between early-stage biomarker discovery and scalable, worldwide clinical application, ensuring that every patient receives the most accurate diagnosis for personalized treatment.